Drug reference
Adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing delayed nausea and vomiting associated with moderately and highly emetogenic chemotherapy ▶BY MOUTH ▶Adult: 180 mg as a single dose, dose should be administered up to 2 hours before chemotherapy. Interval between repeated doses must be at least 2 weeks, consult product literature for dose of concomitant corticosteroid and 5HT3-antagonist
PDF page 476
Scottish Medicines Consortium (SMC) decisions SMC No. 1266/17 The Scottish Medicines Consortium has advised (September 2017) that rolapitant (Varuby ®) is accepted for restricted use within NHS Scotland as a first-line option for the prevention of delayed nausea and vomiting in adults undergoing highly emetogenic chemotherapy. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower. All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 1303 The All Wales Medicines Strategy Group has advised (March 2018) that rolapitant (Varuby ®) is not recommended for use within NHS Wales for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. The case for cost-effectiveness has not been proven.
PDF page 476
→Appendix 1: rolapitant
PDF page 476
▶Common or very common Asthenia. constipation. headache ▶Uncommon Appetite decreased. concentration impaired. diarrhoea. dizziness. drowsiness. gastrointestinal discomfort. hiccups. increased risk of infection. insomnia . myalgia. nausea. neutropenia. stomatitis. taste altered ▶Rare or very rare Alopecia. angioedema. anxiety. arthralgia. back pain. dehydration. dry mouth. dyspnoea. gait abnormal. gastrointestinal disorders. hearing impairment. hypertension. hypomagnesaemia. leucopenia. movement disorders. muscle weakness. rhabdomyolysis. skin reactions. syncope. teeth grinding. thrombocytopenia. tinnitus. vision blurred. vomiting
PDF page 476
Manufacturer advises avoid unless potential benefit outweighs risk—limited information available.
PDF page 476
Manufacturer advises avoid—present in milk in animal studies.
PDF page 476
Manufacturer advises caution in severe impairment (no information available).
PDF page 476
Manufacturer advises use with caution in severe impairment—limited information available.
PDF page 476
No licensed medicines listed. ANTIEMETICS AND ANTINAUSEANTS › SEROTONIN (5HT3) RECEPTOR ANTAGONISTS
PDF page 476
180 mg as a single dose, dose should be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 476
